Is Relypsa (NASDAQ:RLYP) Finally Worth Your Time? What Does H.C. Wainwright Think?


Why Has H.C. Wainwright Given Relypsa (NASDAQ:RLYP) a $63.0 Price Target

Analysts at H.C. Wainwright have commenced coverage coverage on shares of Relypsa (NASDAQ:RLYP) in a recent research report issued on 17 December. The firm set Buy rating on the $1.15 billion market cap company.

From a total of 8 analysts covering Relypsa (NASDAQ:RLYP) stock, 8 rate it a ”Buy”, 1 a “Sell”, and 0 a ”Hold”. This means that 89% of the ratings are positive. The highest target price is $75 while the lowest target price is $9. The mean of all analyst targets is $43.25 with a 68.84% above today’s ($28.31) stock price. Relypsa was the topic of 9 analyst reports since July 30, 2015 according to the firm StockzIntelligence Inc. Guggenheim initiated shares on November 5 with “Buy” rating. Morgan Stanley initiated shares with “Underweight” rating and $15 target share price in a report from an August 13. Wedbush maintained RLYP stock in a recent report from October 22 with “Outperform” rating. Stifel Nicolaus maintained the rating on August 11. Stifel Nicolaus has a “Buy” rating and a $48 price target on shares. Finally, Citigroup initiated the stock with “Buy” rating in a report issued on a September 3.

The stock increased 2.95% or $0.81 during the last trading session, striking $28.31. Approximately 10 shares of stock traded hands. Relypsa Inc (NASDAQ:RLYP) has declined 21.30% since May 14, 2015 and is downtrending. It has underperformed by 19.03% the S&P500.

The overall sentiment of institutions has decreased to 1.42 in Q2 2015. Its down 0.86, from 2.28 in 2015Q2. The ratio turned negative, as 26 institutions have sold all the shares of Relypsa Inc that they owned while 27 funds have taken shares off the table. 18 funds have purchased shares for the first time while 57 added to their positions. These institutions now hold 36.63 million shares or 2.92% more than the 35.59 million shares they owned in 2015Q2.

The Fund Great Point Partners Llc currently is holding shares equating to 5.63% of its total portfolio in Relypsa Inc representing a total of 769,047 shares. Another fund,Jhl Capital Group Llc, is holding a total of 1.80 million shares equating to 3.68% of their holdings. Additionally, Perceptive Advisors Llc has a 987,942 share stake in Relypsa Inc which represents 1.46% of their total portfolio. The Fund, Orbimed Advisors Llc, based out of New York, has also built up a stake in the stock, which represents a total of 1.38% of their total portfolio. Finally New Leaf Venture Partners L.L.C., a fund which is based in the state of New York reported a total holdings of 65,961 shares.

Insider activity is a very important aspect to track on any stock. Going back to March 5, 2015, shareholders of Relypsa Inc have witnessed 1 insider buy, and a total of 9 selling transactions equating to a net activity of approximately $5.05 million . Orbimed Advisors Llc bought 500,000 shares worth approximately $6.28M. Ball Kristine M sold 646 shares worth approximately $14,832. Lockey Claire sold 522 shares worth approximately $12,888. Stahl Wilhelm sold 522 shares worth approximately $12,894. The company insider Orwin John A sold 5,000 shares worth $124,183.

Relypsa, Inc. is a biopharmaceutical firm focused on the development and commercialization of non-absorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases. The company has a market cap of $1.15 billion. The Company’s lead product candidate, Patiromer for Oral Suspension is for the treatment of hyperkalemia, a life-threatening condition defined as abnormally elevated levels of potassium in the blood. It currently has negative earnings. The Company’s New Drug Application (NDA) for Patiromer FOS was accepted for filing by the United States Food and Drug Administration, or FDA.

According to Zacks Investment Research, “Relypsa, Inc. is a pharmaceutical company focused on the development and commercialization of nonabsorbed polymeric drugs to treat disorders in the areas of renal, cardiovascular and metabolic diseases. Relypsa, Inc. is headquartered in Redwood City, California.”